<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00794872</url>
  </required_header>
  <id_info>
    <org_study_id>Chemoreflex-Sensitivity-Study</org_study_id>
    <nct_id>NCT00794872</nct_id>
  </id_info>
  <brief_title>Chemoreflex Sensitivity in Chronic Kidney Disease</brief_title>
  <official_title>Hyperoxic Chemoreflex Sensitivity in Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Clinic I, SLK-Kliniken Heilbronn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular morbidity and mortality are markedly increased in chronic kidney disease (CKD)
      and may be explained in part by sympathetic hyperactivity. Impaired hyperoxic chemoreflex
      sensitivity (CHRS) has been attributed to an increased sympathetic activity. The aim of the
      present study is to examine whether chemosensor function is altered in patients with stage 3
      and stage 4 CKD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Impaired hyperoxic chemoreflex sensitivity (CHRS) is assessed in patients with stage 3 CKD
      [glomerular filtration rate (GFR) 30-59 ml/min/1.73 m2], in patients with stage 4 CKD [GFR
      15-29 ml/min/1.73 m2], as well as in patients without any evidence of CKD. CHRS is measured
      by determination of the venous partial pressure of oxygen and the heart rate before and after
      deactivation of the chemoreceptors by inhalation of pure oxygen. The difference in the R-R
      intervals before and after inhalation divided by the difference in the oxygen pressures is
      calculated as the CHRS. A CHRS below 3.0 ms/mmHg is defined as pathological. It should be
      shown that using a simple clinical bedside test we provide the first evidence for impaired
      hyperoxic chemoreflex sensitivity in stage 3 and 4 chronic kidney disease. We thereby may lay
      the basis for future intervention studies assessing chemosensor function in these patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hyperoxic chemoreflex sensitivity is impaired in patients with moderate to severe chronic kidney disease</measure>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">65</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Cardiovascular Morbidity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients with stage 3 CKD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Patients with stage 4 CKD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Patients without evidence for CDK</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sampling</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Measurement of the venous partial pressure of oxygen in blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suffering from CDK stage 3 (GFR 30-59 ml/min/1.73 m²) or stage 4 (GFR 15-29
             ml/min/1.73 m²)

          -  For the reference Patients without evidence for CDK

        Exclusion Criteria:

          -  Patients with heart failure, history of myocardial infarction or instable angina
             pectoris, atrial fibrillation, hyperthyroidism, chronic pulmonary diseases, sleep
             apnoea syndrome, alcohol abuse and drug induced cardiomyopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Meyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RWTH Aachen University Departement of Cardiology, Pulmonology and Vascular Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine, Division of Cardiology, Pulmonology and Vascular Medicine</name>
      <address>
        <city>Aachen</city>
        <state>NRW</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2008</study_first_submitted>
  <study_first_submitted_qc>November 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2008</study_first_posted>
  <last_update_submitted>November 19, 2008</last_update_submitted>
  <last_update_submitted_qc>November 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2008</last_update_posted>
  <responsible_party>
    <name_title>Christian Meyer, MD</name_title>
    <organization>RWTH Aachen University</organization>
  </responsible_party>
  <keyword>Cardiovascular autonomic neuropathy</keyword>
  <keyword>Chemoreflex sensitivity</keyword>
  <keyword>Chronic kidney disease</keyword>
  <keyword>Sudden cardiac arrest</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

